Anthem Biosciences Limited is one of India’s fastest-growing, innovation-led CRDMOs, offering end-to-end services from drug discovery to commercial manufacturing. Founded in 2007, it has swiftly emerged as a leader in the pharmaceutical outsourcing space, serving global biotech and pharma clients. As per the F&S Report, Anthem is the fastest Indian CRDMO to surpass ₹1,000 crore in revenue, achieving this in just 14 years.

Core Business Segments

Anthem operates two synergistic businesses:

1. CRDMO Services:
A one-stop solution for New Chemical Entities (NCEs) and New Biological Entities (NBEs), offering services from target identification to commercial manufacturing. The company is a pioneer in cutting-edge modalities including RNA interference (RNAi), Antibody-Drug Conjugates (ADCs), peptides, lipids, and oligonucleotides. It holds the distinction of being the only Indian CRDMO with strong capabilities in both small and large molecule biologics.

2. Specialty Ingredients:
Manufactures and sells fermentation-based Active Pharmaceutical Ingredients (APIs) such as probiotics, enzymes, nutritional actives, and biosimilars. These offerings serve both regulated markets (US, Europe) and semi-regulated markets (India, Southeast Asia, Latin America).

Technological & Operational Strengths

Anthem has made consistent investments in advanced technologies, such as Flow chemistry, Biotransformation and enzymatic synthesis, Continuous manufacturing and Green chemistry techniques (pincer catalysis, micellar technology).

It has three manufacturing units (two operational, one under construction) and holds the largest fermentation capacity among Indian CRDMOs at 142 kL, expected to grow to 182 kL by mid-2025. All facilities are cGMP-compliant and accredited by global regulators like the US FDA, ANVISA (Brazil), TGA (Australia), and PMDA (Japan).

Customer Base & Strategic Partnerships

Anthem Biosciences serves 550+ clients across 44 countries, with nearly 70% of revenue from its top 5 long-term customers. Its US growth is driven by a partnership with DavosPharma, adding 100+ clients, including 92 emerging biotechs. The company’s focus on small biotech firms and Fee-for-Service (FFS) models supports strong margins and global expansion.

Market Opportunity

The global pharmaceutical and CRDMO industries are on a strong growth trajectory:

– Global pharma market projected to reach $1.96 trillion by 2028
– Indian CRDMO market expected to grow at a 14% CAGR (2023–2028), outpacing global peers

Tailwinds such as China+1 strategy, global demand for integrated solutions, and increasing biologics adoption are positioning India—and Anthem in particular—as a key global CRDMO hub.

Competitive Advantages

i) Integrated services across discovery, development, and manufacturing
ii) Strong presence across both small and large molecule platforms
iii) Differentiated expertise in fast-growing biologic modalities (RNAi, ADCs, etc.)
iv) Industry-leading financial metrics and capital efficiency
v) Early-mover advantage in green and sustainable manufacturing
vi) Deep relationships with emerging biotech clients that scale post-acquisition

To be updated shortly

To be updated shortly